Akari Therapeutics Announces $5.5 Million Private Placement Offering
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) priced a private placement expected to raise approximately $5.5 million in gross proceeds. The company will sell 1,470,588 ADSs or prefunded warrants, plus unregistered Series H, I and J warrants priced at $3.74 per ADS.
Akari plans to use net proceeds for working capital, general corporate purposes, and to advance lead ADC candidate AKTX-101 toward a first-in-human Phase 1 trial. Closings are expected in three tranches between May 27 and July 15, 2026.
Positive
- Private placement expected to raise approximately $5.5 million gross
- Issue price set at $3.74 per ADS with defined warrant terms
- Proceeds earmarked to advance lead ADC AKTX-101 toward Phase 1 trial
- Three closing tranches provide staged funding between May 27 and July 15, 2026
Negative
- Potential dilution from 1,470,588 new ADSs plus up to 4,411,764 warrant ADSs
- All Series H, I and J warrants share an exercise price of $3.74, extending over up to 60 months
News Market Reaction – AKTX
In the May 21 session, AKTX gained 49.85%, reflecting a significant positive market reaction. Argus tracked a peak move of +499.4% during that session. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 61 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 617.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Private placement,offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 16 | Equity financing | Negative | -38.3% | At-market registered direct and private placement totaling about $5M with warrants. |
| Mar 03 | Private placement | Negative | +7.7% | Private placement for $7.6M with ADSs and warrants led by insiders. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
For past private placement/offering events, AKTX showed mixed reactions, with an average move of about -15.3% and one positive, one sharply negative response.
Recent AKTX history shows repeated financings alongside development of its ADC platform. Two prior private placement/offering announcements in March 2025 and December 2025 raised roughly mid-single-digit millions and featured ADSs plus warrants. Price reactions diverged, with one +7.7% move and one -38.3% drop, yielding an average move of -15.3%. Today’s private placement continues this pattern of equity-linked capital raises to fund preclinical ADC development.
Key Terms
private placement financial
prefunded warrants financial
warrants financial
placement agent financial
section 4(a)(2) regulatory
regulation d regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately
“This financing reflects deep conviction from our long-term strategic investors and positions Akari to build on our strong momentum to accelerate our lead ADC program towards clinical data, pursue strategic partnerships, and unlock the full potential of our novel ADC platform,” stated, Abizer Gaslightwala, Akari’s CEO.
The Company entered into definitive purchase agreements with the investors for the issuance and sale of 1,470,588 unregistered American Depository Shares (ADSs), or prefunded warrants in lieu thereof, and unregistered Series H Warrants, Series I Warrants and Series J Warrants (“the Offering”). The ADSs were priced at
The gross cash proceeds from the Offering are expected to be approximately
The issuance of the Series H, I and J Warrants is subject to the Company obtaining shareholder approval and will each be exercisable for 1,470,588 ADSs. The Series H Warrants will have an exercise price of
Paulson Investment Company LLC is acting as placement agent for the financing. The gross proceeds of the private placement will be funded in three separate tranches pursuant to three separate closings, expected to occur between May 27, 2026 and July 15, 2026.
The ADSs and warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and have not been registered under the Act or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the offering, the use of proceeds, the expected gross proceeds and the expected closing of the offering. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
